InsiderTrades.com logo
Douglas Love net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Douglas Love Biography and Net Worth

CEO of Annexon
Mr. Love joined Annexon Biosciences as President and Chief Executive Officer in December 2014 with extensive business and legal leadership experience in biotech. He previously served as Head of Operations for Elan Pharmaceuticals. There, Mr. Love led the Tysabri® multiple sclerosis franchise, helping to propel it to nearly $2 billion in annual sales. He also led Elan’s Alzheimer’s Immunotherapy Program, which was licensed to Johnson & Johnson for $1 billion plus milestones and royalties, as well as Elan’s global Commercial, Medical Affairs and Alliance Management groups. Mr. Love is a corporate attorney by training, and prior to joining Elan, served as an associate at the law firm Orrick, Herrington & Sutcliffe, Corporate Counsel at Amgen, Inc. and as Section Corporate Counsel at Genentech Inc., where he led the BioOncology Healthcare Law Group and launched several blockbuster programs. Mr. Love holds a J.D. with great distinction from McGeorge School of Law, Sacramento, CA, and a B.S. in business administration from the University of Southern California.

What is Douglas Love's net worth?

The estimated net worth of Douglas Love is at least $790,996.50 as of February 13th, 2025. Mr. Love owns 351,554 shares of Annexon stock worth more than $790,997 as of March 29th. This net worth estimate does not reflect any other investments that Mr. Love may own. Additionally, Mr. Love receives a salary of $980,120.00 as CEO at Annexon. Learn More about Douglas Love's net worth.

How old is Douglas Love?

Mr. Love is currently 56 years old. There are 5 older executives and no younger executives at Annexon. Learn More on Douglas Love's age.

What is Douglas Love's salary?

As the CEO of Annexon, Inc., Mr. Love earns $980,120.00 per year. Learn More on Douglas Love's salary.

How do I contact Douglas Love?

The corporate mailing address for Mr. Love and other Annexon executives is , , . Annexon can also be reached via phone at 650-822-5500 and via email at swheeler@wheelhouselsa.com. Learn More on Douglas Love's contact information.

Has Douglas Love been buying or selling shares of Annexon?

Within the last three months, Douglas Love has sold $14,811.95 in shares of Annexon stock. Most recently, Douglas Love sold 5,021 shares of the business's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $2.95, for a transaction totalling $14,811.95. Following the completion of the sale, the chief executive officer now directly owns 351,554 shares of the company's stock, valued at $1,037,084.30. Learn More on Douglas Love's trading history.

Who are Annexon's active insiders?

Annexon's insider roster includes Sanjay Keswani (EVP), Jennifer Lew (CFO), Douglas Love (CEO), and Ted Yednock (EVP). Learn More on Annexon's active insiders.

Are insiders buying or selling shares of Annexon?

During the last twelve months, Annexon insiders bought shares 5 times. They purchased a total of 16,000 shares worth more than $89,984.00. During the last twelve months, insiders at the sold shares 12 times. They sold a total of 48,976 shares worth more than $224,444.81. The most recent insider tranaction occured on February, 18th when insider Jamie Dananberg sold 5,521 shares worth more than $16,342.16. Insiders at Annexon own 12.7% of the company. Learn More about insider trades at Annexon.

Information on this page was last updated on 2/18/2025.

Douglas Love Insider Trading History at Annexon

See Full Table

Douglas Love Buying and Selling Activity at Annexon

This chart shows Douglas Love's buying and selling at Annexon by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$15ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100k$0$100kTotal Insider BuyingTotal Insider Selling

Annexon Company Overview

Annexon logo
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Read More

Today's Range

Now: $2.25
Low: $2.21
High: $2.31

50 Day Range

MA: $3.05
Low: $2.24
High: $4.24

2 Week Range

Now: $2.25
Low: $2.18
High: $7.85

Volume

1,086,710 shs

Average Volume

1,758,707 shs

Market Capitalization

$246.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.14